Abstract 99P
Background
Patients with chemotherapy-responsive advanced biliary tract cancer (BTC) are usually observed post 6 months of gemcitabine-based therapy, though most progress within a short time-span and there is limited prospective evidence for maintenance strategies.
Methods
The study is an integrated phase II – III randomised clinical trial (Clinical Trial Registry of India number: CTRI/2017/10/010112) conducted at 2 centres in India. Eligible patients with advanced BTC who had responsive or stable disease status post 6 months of gemcitabine – based chemotherapy were randomly assigned (1:1) to either observation arm (O) or intervention arm (BEER), which was a combination of Bevacizumab 5 mg/m2 IV every 21 days plus erlotinib 100 mg once daily, . Both arms were continued till disease progression, significant toxicity or patients choice. The primary endpoint of the phase II component was progression free survival, measured from randomization into the trial.
Results
Between May 2021 and November 2022, 98 patients (O: 48; BEER: 50) comprising 78 patients with gallbladder cancer (GBC) and 20 patients with cholangiocarcinoma (CC) were randomised with all 98 patients included in the final analysis. With a median follow up of 11.2 months, patients in the BEER cohort showed an improved PFS compared to the observation cohort [5.2 months (95% CI: 3.4-6.9) vs. 3 months (95% CI: 2.5 - 3.5); p=0.004]. The CC cohort tended to derive greater benefit from BEER (6.7 months vs. 2.2 months) than the GBC cohort (4.3 months vs. 3 months). There were no grade 3 or grade 4 adverse events noted, though temporary cessation of erlotinib was required due to grade 2 skin rash in 7 patients (14%), and grade 2 oral stomatitis in 1 patient (2%).
Conclusions
The combination of bevacizumab and erlotinib improves progression free survival in patients with chemotherapy responsive advanced BTC in this phase 2 clinical trial. The ongoing phase III component of the study will evaluate whether the significant benefit in PFS translates to improvement in overall survival.
Clinical trial identification
CTRI/2017/10/010112.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cadilla Pharma Pvt Ltd (supported bevacizumab) Dr. Reddy's Lab pvt Ltd (supported bevacizumab) LUPIN Pharma pvt Ltd Intas pvt Ltd.
Disclosure
A. Ramaswamy: Financial Interests, Institutional, Research Grant: Cipla Health Limited, Dr Reddy Laboratories, Zydus Lifesciences. V.S. Ostwal: Financial Interests, Institutional, Funding, IIS: Cadilla Pharmaceuticals pvt Lts, Reddy's pvt Ltd, Lupin, BDR; Financial Interests, Personal, Invited Speaker, GI ESMO 22: AstraZeneca; Financial Interests, Institutional, Advisory Board: Mankind, Natco. All other authors have declared no conflicts of interest.
Resources from the same session
720TiP - Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
Presenter: Abdul-Rafeh Naqash
Session: Poster session 17
722TiP - CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma
Presenter: Radka Obermannova
Session: Poster session 17
732P - Efficacy and safety of high-dose chemotherapy as second or subsequent salvage therapy in relapsed or refractory germ cell cancer patients: A multicentric analysis
Presenter: Christoph Seidel
Session: Poster session 17
733P - Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020
Presenter: David Benjamin
Session: Poster session 17
734P - Primary retroperitoneal germ-cell tumours (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)
Presenter: Patrizia Giannatempo
Session: Poster session 17